Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

THYMOCYTE IMMUNE GLOBULIN NOS: 5,559 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
5,559
Total FAERS Reports
1,474 (26.5%)
Deaths Reported
2,161
Hospitalizations
5,559
As Primary/Secondary Suspect
675
Life-Threatening
22
Disabilities

First Report: 1991 · Latest Report: 20240726

What Are the Most Common THYMOCYTE IMMUNE GLOBULIN NOS Side Effects?

#1 Most Reported
Off label use
749 reports (13.5%)
#2 Most Reported
Drug ineffective
692 reports (12.4%)
#3 Most Reported
Cytomegalovirus infection
404 reports (7.3%)

All THYMOCYTE IMMUNE GLOBULIN NOS Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Off label use 749 13.5% 242 300
Drug ineffective 692 12.5% 226 245
Cytomegalovirus infection 404 7.3% 127 126
Product use in unapproved indication 396 7.1% 122 86
Transplant rejection 340 6.1% 22 68
Post transplant lymphoproliferative disorder 319 5.7% 182 103
Epstein-barr virus infection 255 4.6% 126 58
Pneumonia 254 4.6% 104 104
Multiple organ dysfunction syndrome 250 4.5% 227 119
Coma 247 4.4% 19 231
Pneumonia aspiration 239 4.3% 0 220
Somnolence 235 4.2% 6 223
Cytomegalovirus viraemia 228 4.1% 33 73
Gastrooesophageal reflux disease 227 4.1% 0 216
Pyrexia 224 4.0% 62 137
Cytomegalovirus infection reactivation 215 3.9% 69 79
Bk virus infection 206 3.7% 63 88
Acute kidney injury 204 3.7% 60 104
Transplant dysfunction 190 3.4% 7 14
Condition aggravated 185 3.3% 48 51

Who Reports THYMOCYTE IMMUNE GLOBULIN NOS Side Effects? Age & Gender Data

Gender: 49.3% female, 50.7% male. Average age: 35.4 years. Most reports from: US. View detailed demographics →

Is THYMOCYTE IMMUNE GLOBULIN NOS Getting Safer? Reports by Year

YearReportsDeathsHosp.
2002 3 0 0
2003 3 1 0
2004 7 3 1
2005 5 0 0
2006 1 0 1
2008 1 0 0
2009 15 10 3
2010 16 11 2
2011 19 5 6
2012 22 5 5
2013 22 11 13
2014 46 20 22
2015 44 9 14
2016 79 14 55
2017 64 7 44
2018 73 14 49
2019 58 9 39
2020 69 12 52
2021 40 2 21
2022 48 3 31
2023 18 1 12
2024 5 2 3

View full timeline →

What Is THYMOCYTE IMMUNE GLOBULIN NOS Used For?

IndicationReports
Immunosuppressant drug therapy 1,431
Bone marrow conditioning regimen 742
Prophylaxis against graft versus host disease 614
Product used for unknown indication 494
Immunosuppression 451
Prophylaxis against transplant rejection 308
Allogenic stem cell transplantation 269
Aplastic anaemia 249
Renal transplant 247
Stem cell transplant 233

THYMOCYTE IMMUNE GLOBULIN NOS vs Alternatives: Which Is Safer?

THYMOCYTE IMMUNE GLOBULIN NOS vs THYMOGLOBULINE THYMOCYTE IMMUNE GLOBULIN NOS vs THYMOL THYMOCYTE IMMUNE GLOBULIN NOS vs THYROID, PORCINE THYMOCYTE IMMUNE GLOBULIN NOS vs THYROID, PORCINE\THYROID, UNSPECIFIED THYMOCYTE IMMUNE GLOBULIN NOS vs THYROTROPIN ALFA THYMOCYTE IMMUNE GLOBULIN NOS vs TIAGABINE THYMOCYTE IMMUNE GLOBULIN NOS vs TIANEPTINE THYMOCYTE IMMUNE GLOBULIN NOS vs TIAPRIDE THYMOCYTE IMMUNE GLOBULIN NOS vs TIAPROFENIC ACID THYMOCYTE IMMUNE GLOBULIN NOS vs TICAGRELOR

Official FDA Label for THYMOCYTE IMMUNE GLOBULIN NOS

Official prescribing information from the FDA-approved drug label.